Entelos, Inc. (LSE: ENTL), a U.S.-based life sciences company using predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today that it is extending its technology applications to conduct research using “virtual consumers” for an undisclosed customer in Switzerland. This multi-million dollar research contract will focus on risk assessment and reduction in cardiovascular disease and other disease areas of interest to the customer. Entelos will receive technology license fees and R&D funding for the next three years.

"We are pleased to be expanding the use of our powerful simulation technology to applications in consumer products,” stated James Karis, President and CEO of Entelos. "Our virtual patient populations have already been used successfully with multiple pharmaceutical customers to test for drug safety and efficacy. In this new application, we will be expanding its use to test the effects of ‘virtual products’ on ‘virtual consumers,’ representations of unique genetic, biologic, and lifestyle profiles. We can then use our technology to optimize product designs to improve human health.”

For further information please contact:

Entelos, Inc.
Jill Fujisaki, VP Investor Relations
Tel: +1 650 572 5400

KBC Peel Hunt, Ltd (Nominated Advisor and Broker)

Capel Irwin
Tel +44 (0) 20 4718 8900

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson
Tel +44 (0) 20 7466 5000

  www.entelos.com